about
Inflammatory bowel disease: clinical aspects and established and evolving therapiesNatalizumab Induction and Maintenance Therapy for Crohn's DiseaseA simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesMRI scoring indices for evaluation of disease activity and severity in Crohn’s diseaseEndoscopic scoring indices for evaluation of disease activity in ulcerative colitisTreatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitisPlacebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitisHistologic scoring indices for evaluation of disease activity in ulcerative colitisEndoscopic scoring indices for evaluation of disease activity in Crohn’s diseaseBiomarkers for assessing disease activity in inflammatory bowel diseaseTreatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitisEndoscopic scoring indices for evaluation of disease activity in Crohn’s diseasePlacebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn’s diseaseTreating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseasesDefining Disease Severity in Inflammatory Bowel Diseases: Current and Future DirectionsLymphocytic colitis: clinical features, treatment, and outcomesPredictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control studyCertolizumab pegol for the treatment of Crohn's diseaseHealth-related quality of life during natalizumab maintenance therapy for Crohn's diseaseBudesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trialsCrohn's diseaseInfliximab for induction and maintenance therapy for ulcerative colitisAnti-interleukin-12 antibody for active Crohn's diseaseHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trialLeucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazideMeasurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel diseaseDiagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel diseaseRisk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's DiseaseUstekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseObesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices.Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
P50
Q21957029-A8783D91-EE58-403E-A764-B2D31C0FDD05Q22250890-CB4FC0C3-2AC1-401F-8E6C-233D3B7E4119Q22252901-50A0DCDE-19DD-4A02-B45F-D7D08C7CD34EQ24185835-480B7956-44D2-4DCA-8C7A-44D070E65DC3Q24186977-78D560A4-4BF6-44A2-B406-8A7B39E29394Q24187044-C1DD571F-9A8B-46F1-A366-25415C874B3BQ24187707-0F843BEE-6C2E-4C55-A281-E0490B5958E8Q24187737-EF722780-F787-46FD-9110-7FD0F0F69066Q24194674-49B7ACD0-70E4-4F75-975E-DAF2CA48A260Q24201734-A456B136-9DD6-4A33-A9D3-F028351010D1Q24202614-9B0C92EA-2A47-4F9B-BBCE-031BB02295D6Q24234806-28B179EB-FADB-4F31-BEDD-8DDC94CF9984Q26470550-9FEF3847-4B1E-4534-AC50-CF8CF9D98B4AQ26471222-CACBF7DF-329B-441C-A28A-2B6AB401F3F0Q27008246-FF1AE56F-B25C-4996-83BB-CD056C9C5F11Q28087314-A6537A98-E441-4C77-B877-2A76FB581E47Q28194164-950C73FA-D81F-4843-8362-7088D30A0B7DQ28218907-0E1D4537-110B-4B83-BCFA-3EA380A31427Q28236746-8F4BBE1C-F3D8-4AC5-8D99-818BACCDAC59Q28258882-A14DFA08-4FD3-4EB0-89AC-84202F44EB1FQ28266279-1B1A7554-24FA-4759-8566-6D3099B086C5Q28273481-DBB7BF51-0BE8-4850-9505-D55D5AE9D6CEQ28285876-E22EDB7F-F5C9-441D-A62F-B15271611AD7Q28292686-66A8C7E5-F3BE-40CD-9D19-4A0A7ADF45EAQ28296771-B830EE7B-1C96-4828-845F-9D8BA4064103Q28361611-349669E3-8591-40C8-B7AA-737BBBD1456BQ28361615-86561AC6-603F-4CF5-9659-30409BFAFECEQ28393838-B1A0F1E3-3E2B-4E27-95DE-F030F9682493Q28538974-946D7520-ECD8-4F4F-9C62-4001306E2CABQ30054715-353869AB-04B1-449E-8B86-11D3E7BD8858Q30239737-2615B169-D1AE-4D0E-96F9-43CB1F249F63Q30248641-A989CEF8-2665-40C7-92FA-E7DF6137C500Q30355181-D6111429-D74C-43B6-A390-A061002B3654Q30662026-3287902B-C56E-4A0F-B08C-2A1C400F871BQ30679247-A1C03ED2-C3D7-4D55-96E6-8C971A87ACEDQ30844786-2EF583E6-7031-478F-B256-BDE82639F857Q30984504-9CA9FDF7-AF67-473E-9A06-9C66B5DEDFCBQ31113830-38B31641-9E70-41AA-A3D5-EE3CC7E39CCCQ31148096-9C4247CC-FD43-4798-A9F6-33D099685834Q33343338-6FD9218A-6C66-4722-BA84-85DEBD1D3749
P50
subject
description
Amerikaans onderzoeker
@nl
forsker
@nb
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
William Jeffery Sandborn
@ast
William Jeffery Sandborn
@da
William Jeffery Sandborn
@de
William Jeffery Sandborn
@en
William Jeffery Sandborn
@es
William Jeffery Sandborn
@fr
William Jeffery Sandborn
@nb
William Jeffery Sandborn
@nl
William Jeffery Sandborn
@nn
William Jeffery Sandborn
@sv
type
label
William Jeffery Sandborn
@ast
William Jeffery Sandborn
@da
William Jeffery Sandborn
@de
William Jeffery Sandborn
@en
William Jeffery Sandborn
@es
William Jeffery Sandborn
@fr
William Jeffery Sandborn
@nb
William Jeffery Sandborn
@nl
William Jeffery Sandborn
@nn
William Jeffery Sandborn
@sv
altLabel
William J Sandborn
@en
William J. Sandborn
@nb
William Sandborn
@nb
prefLabel
William Jeffery Sandborn
@ast
William Jeffery Sandborn
@da
William Jeffery Sandborn
@de
William Jeffery Sandborn
@en
William Jeffery Sandborn
@es
William Jeffery Sandborn
@fr
William Jeffery Sandborn
@nb
William Jeffery Sandborn
@nl
William Jeffery Sandborn
@nn
William Jeffery Sandborn
@sv
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0002-3314-7960
P7859
lccn-no2004014791